MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Kura Oncology Inc

Cerrado

SectorSanidad

6.54 2.99

Resumen

Variación precio

24h

Actual

Mínimo

6.23

Máximo

6.54

Métricas clave

By Trading Economics

Ingresos

35M

-19M

Ventas

54M

54M

BPA

-0.22

Margen de beneficios

-35.664

Empleados

192

EBITDA

43M

-17M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+311.44% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-43M

570M

Apertura anterior

3.55

Cierre anterior

6.54

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

146 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 23:55 UTC

Acciones populares

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 abr 2025, 22:50 UTC

Principales Movimientos del Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 abr 2025, 21:08 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 abr 2025, 21:00 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 abr 2025, 23:56 UTC

Charlas de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 abr 2025, 23:44 UTC

Principales Noticias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 abr 2025, 23:32 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 23:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 23:32 UTC

Charlas de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 abr 2025, 23:10 UTC

Charlas de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:57 UTC

Charlas de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 abr 2025, 22:56 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:56 UTC

Charlas de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 abr 2025, 22:43 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 abr 2025, 22:12 UTC

Charlas de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 abr 2025, 21:48 UTC

Principales Noticias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 abr 2025, 21:41 UTC

Charlas de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 21:17 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 abr 2025, 21:04 UTC

Principales Noticias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 abr 2025, 21:03 UTC

Charlas de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 abr 2025, 20:53 UTC

Ganancias

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 abr 2025, 20:52 UTC

Ganancias

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

311.44% repunte

Estimación a 12 Meses

Media 26.25 USD  311.44%

Máximo 40 USD

Mínimo 10 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

12

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.27 / 7.14Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

146 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.